Related references
Note: Only part of the references are listed.Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma
Donna E. Hansel et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound-Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
Diana Cirstea et al.
MOLECULAR CANCER THERAPEUTICS (2010)
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K
J. M. Askham et al.
ONCOGENE (2010)
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
C. A. Sparks et al.
ONCOGENE (2010)
A complex interplay between Akt, TSC2 and the two mTOR complexes
Jingxiang Huang et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
Margaret A. Knowles et al.
CANCER AND METASTASIS REVIEWS (2009)
Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer
Catherine M. Seager et al.
CANCER PREVENTION RESEARCH (2009)
Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin
Dingxie Liu et al.
CANCER RESEARCH (2009)
Activation of the PI3K/AKT Pathway Induces Urothelial Carcinoma of the Renal Pelvis: Identification in Human Tumors and Confirmation in Animal Models
Chao-Nan Qian et al.
CANCER RESEARCH (2009)
Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk
Meng Chen et al.
CARCINOGENESIS (2009)
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
Fiona M. Platt et al.
CLINICAL CANCER RESEARCH (2009)
PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Peng Wu et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Dexin Kong et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Current Perspectives on Akt Akt-ivation and Akt-ions
Ronald W. Matheny et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2009)
Targeting the mTOR pathway using deforolimus in cancer therapy
Devalingam Mahalingam et al.
FUTURE ONCOLOGY (2009)
Inactivation of p53 and Pten promotes invasive bladder cancer
Anna M. Puzio-Kuter et al.
GENES & DEVELOPMENT (2009)
Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells
Shigeru Kanda et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model
Ruifang Mi et al.
JOURNAL OF GENETICS AND GENOMICS (2009)
New insights into the role of the tuberous sclerosis genes in leukemia
Margit Rosner et al.
LEUKEMIA RESEARCH (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis
Deliang Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
MTORCI inhibitors: is temsirolimus in renal cancer telling us how they really work?
C. Le Tourneau et al.
BRITISH JOURNAL OF CANCER (2008)
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy
Xuerong Wang et al.
CANCER BIOLOGY & THERAPY (2008)
UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers
Sun-Young Kong et al.
CANCER SCIENCE (2008)
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110α/p85α
Chuan-Hsiang Huang et al.
CELL CYCLE (2008)
Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
Bing-Hua Jiang et al.
DRUG RESISTANCE UPDATES (2008)
Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells
Isaya Hashimoto et al.
EUROPEAN JOURNAL OF CANCER (2008)
Akt as a therapeutic target in cancer
Linda S. Steelman et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms
Louis S. Pymar et al.
HUMAN MOLECULAR GENETICS (2008)
ATP modulates PTEN subcellular localization in multiple cancer cell lines
Glenn P. Lobo et al.
HUMAN MOLECULAR GENETICS (2008)
Cotargeting survival signaling pathways in cancer (vol 118 pg 3003, 2008)
Steven Grant
JOURNAL OF CLINICAL INVESTIGATION (2008)
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Jorge A. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray
Loleta D. Harris et al.
MOLECULAR CARCINOGENESIS (2008)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
L. S. Steelman et al.
LEUKEMIA (2008)
Class IPI3K in oncogenic cellular transformation
L. Zhao et al.
ONCOGENE (2008)
Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy
O. Hans Iwenofu et al.
MODERN PATHOLOGY (2008)
Phosphatidylinositol 3-kinase/protein kinase B pathway stabilizes DNA methyltransferase I protein and maintains DNA methylation
Lidong Sun et al.
CELLULAR SIGNALLING (2007)
The green tea compound, (-)-epigallocatechin-3-gallate downregulates N-cadherin and suppresses migration of bladder carcinoma cells
Kimberly M. Rieger-Christ et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
Daniel Cho et al.
CLINICAL GENITOURINARY CANCER (2007)
Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway
Samy Lamouille et al.
JOURNAL OF CELL BIOLOGY (2007)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Lao H. Saal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins
Jie Qin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
Chromosomal deletions in bladder cancer: shutting down pathways
Reimar Abraham et al.
FRONTIERS IN BIOSCIENCE (2007)
Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification
Anirban P. Mitra et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand
Natsuo Oka et al.
CANCER SCIENCE (2006)
mTOR and cancer: insights into a complex relationship
David M. Sabatini
NATURE REVIEWS CANCER (2006)
Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients
Hiroshi Tsuruta et al.
CANCER RESEARCH (2006)
Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced sotid tumours
Stefan R. Vink et al.
RADIOTHERAPY AND ONCOLOGY (2006)
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors
Elena Lopez-knowles et al.
CANCER RESEARCH (2006)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
Rapamycin: An anti-cancer immunosuppressant?
BK Law
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis
JH Chung et al.
CANCER RESEARCH (2005)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
An expanding role for mTOR in cancer
DA Guertin et al.
TRENDS IN MOLECULAR MEDICINE (2005)
Functional analysis of PIK3CA gene mutations in human colorectal cancer
T Ikenoue et al.
CANCER RESEARCH (2005)
MTOR-targeted therapy of cancer with rapamycin derivatives
S Vignot et al.
ANNALS OF ONCOLOGY (2005)
mTOR, translational control and human disease
AR Tee et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2005)
Restraining PI3K: mTOR signalling goes back to the membrane
LS Harrington et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
Dysregulation of the TSC-mTOR pathway in human disease
K Inoki et al.
NATURE GENETICS (2005)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
A Panwalkar et al.
CANCER (2004)
PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity
JJ Gildea et al.
ONCOGENE (2004)
The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion
X Wu et al.
BJU INTERNATIONAL (2004)
Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3k using LY294002
AK Gupta et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
What we could do now: molecular pathology of bladder cancer
MA Knowles
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2001)
Phosphoinositide 3-kinase inhibition in cancer treatment
CP Berrie
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2001)
Regulation of translation initiation by FRAP/mTOR
AC Gingras et al.
GENES & DEVELOPMENT (2001)
Epidemiology and prevention of bladder cancer
E Negri et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2001)
Share Paper
